PDS Biotechnology entered into a Securities Purchase Agreement for a $6 million promissory note and warrants to purchase 2,158,274 shares of common stock. The promissory note carries a 10% annual interest rate and matures in 12 months. The company is using the proceeds to redeem existing senior secured convertible debentures at 103% of their principal amount. A new at-the-market (ATM) sales agreement was established with Yorkville Securities, LLC, replacing a prior agreement with B. Riley and H.C. Wainwright. The transaction is expected to close on or around June 12, 2026.